Terms: = Breast cancer AND MALAT1, PRO1073, 378938, Q9UHZ2 AND Treatment
31 results:
1. [JAG1 affects monocytes-macrophages to reshape the pre-metastatic niche of triple-negative breast cancer through LncRNA malat1 in exosomes].
Xu M; Shi Y; Liu J; Wu M; Zhang F; He Z; Tang M
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Sep; 43(9):1525-1535. PubMed ID: 37814867
[TBL] [Abstract] [Full Text] [Related]
2. Targeted Inhibition of lncRNA malat1 Alters the Tumor Immune Microenvironment in Preclinical Syngeneic Mouse Models of Triple-Negative breast cancer.
Adewunmi O; Shen Y; Zhang XH; Rosen JM
Cancer Immunol Res; 2023 Nov; 11(11):1462-1479. PubMed ID: 37603945
[TBL] [Abstract] [Full Text] [Related]
3. The malat1-breast cancer interplay: insights and implications.
Tufail M
Expert Rev Mol Diagn; 2023; 23(8):665-678. PubMed ID: 37405385
[TBL] [Abstract] [Full Text] [Related]
4. Identification of Hub Genes and Upstream Regulatory Factors Based on Cell Adhesion in Triple-negative breast cancer by Integrated Bioinformatical Analysis.
Han YH; Wang Y; Lee SJ; Mao YY; Jiang P; Sun HN; Jin MH; Kwon T
Anticancer Res; 2023 Jul; 43(7):2951-2964. PubMed ID: 37351977
[TBL] [Abstract] [Full Text] [Related]
5. Metformin and long non-coding RNAs in breast cancer.
Gholami M; Klashami ZN; Ebrahimi P; Mahboobipour AA; Farid AS; Vahidi A; Zoughi M; Asadi M; Amoli MM
J Transl Med; 2023 Feb; 21(1):155. PubMed ID: 36849958
[TBL] [Abstract] [Full Text] [Related]
6. HIF-1α/malat1/miR-141 Axis Activates Autophagy to Increase Proliferation, Migration, and Invasion in Triple-negative breast cancer.
Xu F; Hu Y; Gao J; Wang J; Xie Y; Sun F; Wang L; Miyamoto A; Xia O; Zhang C
Curr Cancer Drug Targets; 2023; 23(5):363-378. PubMed ID: 36579395
[TBL] [Abstract] [Full Text] [Related]
7. lncRNA
Shi C; Ren S; Zhao X; Li Q
Pharmacogenomics; 2022 Dec; 23(18):973-985. PubMed ID: 36420706
[No Abstract] [Full Text] [Related]
8. Baicalin suppresses the migration and invasion of breast cancer cells via the TGF-β/lncRNA-malat1/miR-200c signaling pathway.
Li J; Liu H; Lin Q; Chen H; Liu L; Liao H; Cheng Y; Zhang X; Wang Z; Shen A; Chen G
Medicine (Baltimore); 2022 Nov; 101(46):e29328. PubMed ID: 36401368
[TBL] [Abstract] [Full Text] [Related]
9. Long non-coding RNAs as novel prognostic biomarkers for breast cancer in Egyptian women.
El-Helkan B; Emam M; Mohanad M; Fathy S; Zekri AR; Ahmed OS
Sci Rep; 2022 Nov; 12(1):19498. PubMed ID: 36376369
[TBL] [Abstract] [Full Text] [Related]
10. Functional roles of long noncoding RNA malat1 in gynecologic cancers.
Farzaneh M; Najafi S; Dari MAG; Sheykhi-Sabzehpoush M; Dayer D; Cheraghzadeh M; Azizidoost S
Clin Transl Oncol; 2023 Jan; 25(1):48-65. PubMed ID: 36042115
[TBL] [Abstract] [Full Text] [Related]
11. microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.
Jiang K; Zou H
Bioengineered; 2022 Jan; 13(1):917-929. PubMed ID: 34968160
[TBL] [Abstract] [Full Text] [Related]
12. Roles of the Immune/Methylation/Autophagy Landscape on Single-Cell Genotypes and Stroke Risk in breast cancer Microenvironment.
Wu JY; Qin J; Li L; Zhang KD; Chen YS; Li Y; Jin T; Xu JM
Oxid Med Cell Longev; 2021; 2021():5633514. PubMed ID: 34457116
[TBL] [Abstract] [Full Text] [Related]
13. Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling.
Vishnubalaji R; Alajez NM
Sci Rep; 2021 Jul; 11(1):15410. PubMed ID: 34326372
[TBL] [Abstract] [Full Text] [Related]
14. lncRNA malat1 participates in metformin inhibiting the proliferation of breast cancer cell.
Huang Y; Zhou Z; Zhang J; Hao Z; He Y; Wu Z; Song Y; Yuan K; Zheng S; Zhao Q; Li T; Wang B
J Cell Mol Med; 2021 Aug; 25(15):7135-7145. PubMed ID: 34164906
[TBL] [Abstract] [Full Text] [Related]
15. Tetraarsenic oxide affects non-coding RNA transcriptome through deregulating polycomb complexes in MCF7 cells.
Jeong J; Hamza MT; Kang K; Jo DS; Bae IJ; Kim D; Cho DH; Bunch H
Adv Biol Regul; 2021 May; 80():100809. PubMed ID: 33932728
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic Value of Differentially Expressed LncRNAs in Triple-Negative breast cancer: A Systematic Review and Meta-Analysis.
Tuluhong D; Dunzhu W; Wang J; Chen T; Li H; Li Q; Wang S
Crit Rev Eukaryot Gene Expr; 2020; 30(5):447-456. PubMed ID: 33389881
[TBL] [Abstract] [Full Text] [Related]
17. MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer.
Barsoum FS; Awad AS; Hussein NH; Eissa RA; El Tayebi HM
Pathol Res Pract; 2020 Dec; 216(12):153274. PubMed ID: 33171372
[TBL] [Abstract] [Full Text] [Related]
18. The expression of lncRNA-malat1 in breast cancer patients and its influences on prognosis.
Sun Z; Liu J; Liu J
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):72-78. PubMed ID: 32538750
[TBL] [Abstract] [Full Text] [Related]
19. Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.
Eismann J; Heng YJ; Waldschmidt JM; Vlachos IS; Gray KP; Matulonis UA; Konstantinopoulos PA; Murphy CJ; Nabavi S; Wulf GM
J Cancer Res Clin Oncol; 2020 Feb; 146(2):503-514. PubMed ID: 31745703
[TBL] [Abstract] [Full Text] [Related]
20. Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer.
Özgür E; Ferhatoğlu F; Şen F; Saip P; Gezer U
Cancer Biomark; 2020; 27(1):11-17. PubMed ID: 31640083
[TBL] [Abstract] [Full Text] [Related]
[Next]
